(-0.40%) 5 051.42 points
(-0.83%) 38 143 points
(-0.65%) 15 611 points
(0.25%) $83.02
(-2.18%) $1.617
(0.21%) $2 343.40
(0.14%) $27.38
(0.98%) $924.75
(-0.28%) $0.932
(-0.18%) $10.96
(-0.41%) $0.799
(-0.04%) $92.29
Live Chart Being Loaded With Signals
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients...
Stats | |
---|---|
Today's Volume | 78 875.00 |
Average Volume | 68 727.00 |
Market Cap | 274.47M |
EPS | $0 ( 2024-03-20 ) |
Next earnings date | ( $-0.470 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.00 |
ATR14 | $0.0250 (0.62%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-04 | Huang Jane | Sell | 9 375 | Restricted Stock Unit |
2024-04-04 | Huang Jane | Buy | 9 375 | Common Stock |
2024-04-04 | Huang Jane | Sell | 3 347 | Common Stock |
2024-03-01 | Lim Bryant David | Buy | 150 000 | Employee Stock Option (right to buy) |
2024-03-01 | Scherle Peggy | Buy | 150 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
99.32 |
Last 98 transactions |
Buy: 26 942 964 | Sell: 353 466 |
Volume Correlation
Prelude Therapeutics Correlation
10 Most Positive Correlations | |
---|---|
XOS | 0.828 |
10 Most Negative Correlations | |
---|---|
BNIXU | -0.842 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Prelude Therapeutics Correlation - Currency/Commodity
Prelude Therapeutics Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-1.17M (0.00 %) |
EPS: | $-2.02 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-331 000 (0.00 %) |
EPS: | $-0.600 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-279 000 (0.00 %) |
EPS: | $-0.450 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.540 |
Financial Reports:
No articles found.
Prelude Therapeutics
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators